HNRNPA2B1 and gastric cancer: To substantiate this intriguing clinical observation in a laboratory setting, we performed cytotoxicity assays, which indicated that hnRNPA2B1 KD substantially enhanced the sensitivity of GC cells to cisplatin (CDDP) treatment, as reflected by a notable decrease in the half maximal inhibitory concentration (IC50) values (Figure 4F).